Ontology highlight
ABSTRACT:
SUBMITTER: Scaltriti M
PROVIDER: S-EPMC3048107 | biostudies-literature | 2011 Mar
REPOSITORIES: biostudies-literature
Scaltriti Maurizio M Eichhorn Pieter J PJ Cortés Javier J Prudkin Ludmila L Aura Claudia C Jiménez José J Chandarlapaty Sarat S Serra Violeta V Prat Aleix A Ibrahim Yasir H YH Guzmán Marta M Gili Magui M Rodríguez Olga O Rodríguez Sonia S Pérez José J Green Simon R SR Mai Sabine S Rosen Neal N Hudis Clifford C Baselga José J
Proceedings of the National Academy of Sciences of the United States of America 20110214 9
Clinical benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified breast cancer remain limited by primary or acquired resistance. To identify potential mechanisms of resistance, we established trastuzumab-resistant HER2 amplified breast cancer cells by chronic exposure to trastuzumab treatment. Genomewide copy-number variation analyses of the resistant cells compared with parental cells revealed a focal amplification of genomic DNA containing the cyclin E gene. In ...[more]